what is the difference between zepbound and compounded tirzepatide TrimRX TrimRX | Switching From Zepbound

People who discontinue GLP-1 drugs regained nearly 22 pounds within a year

The cardiovascular protective mechanisms of GLP-1 receptor agonists are thought to include: Improved glycaemic control , reducing endothelial dysfunction associated with hyperglycaemia Weight reduction , decreasing metabolic stress and inflammation Blood pressure lowering , potentially through effects on fluid balance and vascular function Favourable lipid profile changes , including modest reductions in LDL cholesterol and triglycerides Anti-inflammatory effects , reducing systemic markers of inflammation such as C-reactive protein Regulatory bodies including the MHRA and EMA have not identified thrombotic events as a specific safety concern with GLP-1 receptor agonists

This Perspective provides an overview of recent progress and future directions

Guarrera M, Rebora A